3 results on '"Mariano Ponz-Sarvise"'
Search Results
2. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
- Author
-
Irati Macaya, Aram F. Hezel, Maite G. Fernandez-Barrena, O. Erice, Maria J. Perugorria, Adrian Vallejo, Imanol Arozarena, Jesus M. Banales, Iker Feliu, Mariano Ponz-Sarvise, Matías A. Avila, Borja Ruiz-Fernandez de Cordoba, Michael R. O'Dell, Rodrigo Entrialgo-Cadierno, Sergio Ortiz-Espinosa, S. Vicent, Matthias Evert, Alexandra Muggli, Paula Olaizola, Elizabeth Guruceaga, Diego F. Calvisi, and Fernando Lecanda
- Subjects
0301 basic medicine ,Hydroxymethylglutaryl-CoA Synthase ,Male ,Transcriptional Activation ,FOSL1 ,digestive system ,Cholangiocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,Targeted therapies ,Political science ,transcription factors ,Transcription factors ,Genetics ,Humans ,Cost action ,genetics ,Aged ,Hepatology ,Middle Aged ,targeted therapies ,030104 developmental biology ,030211 gastroenterology & hepatology ,Christian ministry ,Female ,cholangiocarcinoma ,Humanities ,Proto-Oncogene Proteins c-fos - Abstract
[EN] Background & Aims: Cholangiocarcinoma (CCA) is a neoplasia of the biliary tract driven by genetic, epigenetic and transcriptional mechanisms. Herein, we investigated the role of the transcription factor FOSL1, as well as its downstream transcriptional effectors, in the development and progression of CCA. Methods: FOSL1 was investigated in human CCA clinical samples. Genetic inhibition of FOSL1 in human and mouse CCA cell lines was performed in in vitro and in vivo models using constitutive and inducible short-hairpin RNAs. Conditional FOSL1 ablation was done using a genetically engineered mouse (GEM) model of CCA (mutant KRAS and Trp53 knockout). Followup RNA and chromatin immunoprecipitation (ChIP) sequencing analyses were carried out and downstream targets were validated using genetic and pharmacological inhibition. Results: An inter-species analysis of FOSL1 in CCA was conducted. First, FOSL1 was found to be highly upregulated in human and mouse CCA, and associated with poor patient survival. Pharmacological inhibition of different signalling pathways in CCA cells converged on the regulation of FOSL1 expression. Functional experiments showed that FOSL1 is required for cell proliferation and cell cycle progression in vitro, and for tumour growth and tumour maintenance in both orthotopic and subcutaneous xenograft models. Likewise, FOSL1 genetic abrogation in a GEM model of CCA extended mouse survival by decreasing the oncogenic potential of transformed cholangiocytes. RNA and ChIP sequencing studies identified direct and indirect transcriptional effectors such as HMGCS1 and AURKA, whose genetic and pharmacological inhibition phenocopied FOSL1 loss. Conclusions: Our data illustrate the functional and clinical relevance of FOSL1 in CCA and unveil potential targets amenable to pharmacological inhibition that could enable the implementation of novel therapeutic strategies. Lay summary: Understanding the molecular mechanisms involved in cholangiocarcinoma (bile duct cancer) development and progression stands as a critical step for the development of novel therapies. Through an inter-species approach, this study provides evidence of the clinical and functional role of the transcription factor FOSL1 in cholangiocarcinoma. Moreover, we report that downstream effectors of FOSL1 are susceptible to pharmacological inhibition, thus providing new opportunities for therapeutic intervention. A.V. was supported by ADA of the University of Navarra, Spain, O.E. by FSE; MINECO; FJCI-2017-34233, Spain, R.E. by a donation from Mauge Burgos de la Iglesia’s family, Spain, and P. Olaizola by the Basque Government (PRE_2016_1_0269), Basque Country, Spain. M.J.P. was funded by ISCIII [FIS PI14; 00399, PI17; 00022] cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER), Spain; Spanish Ministry of Economy and Competitiveness (MINECO: “Ramón y Cajal” Program RYC-2015-17755), Spain. M.A.A was funded by La Caixa Foundation, HEPACARE project, Spain, ISCIII FIS PI16/01126 cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER), Spain, and “Fundación Científica de la Asociación Española Contra el Cáncer’’ (AECC Scientific Foundation) Rare Cancers 2017, Spain. J.M.B. was funded by the Spanish Carlos III Health Institute (ISCIII) (FIS PI15; 01132, PI18; 01075 and Miguel Servet Program CON14; 00129 and CPII19; 00008), Spain, co-financed by “Fondo Europeo de Desarrollo Regional” (FEDER), Spain; “Euskadi RIS3” (2019222054) and BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15; CA; 016; BD), Basque Country, Spain; “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC Scientific Foundation) Rare Cancers 2017, Spain. S.V. was supported by FEDER; MINECO (SAF2017-89944-R), Spain, by the Government of Navarra-Health Research Department (58; 2018), Navarra, Spain, by La Caixa and Caja Navarra Foundation-CIMA agreement, Spain. None of the funding sources were involved in the decision to submit the article for publication. This article is based upon work from COST Action CA18122 European Cholangiocarcinoma Network, supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks (www.cost.eu).
- Published
- 2021
3. Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
- Author
-
L. Resano, P. Martin Romano, I. Melero, M.E. Rodriguez Ruiz, I. Baraibar Argota, A. Chopitea Ortega, E. Castanon Alvarez, Mariano Ponz-Sarvise, and Miguel F. Sanmamed
- Subjects
Oncology ,Chemotherapy ,medicine.medical_specialty ,Gastrointestinal tumors ,business.industry ,medicine.medical_treatment ,Hematology ,Immunotherapy ,030204 cardiovascular system & hematology ,Chemotherapy regimen ,03 medical and health sciences ,0302 clinical medicine ,Progression free survival (PFS) ,030220 oncology & carcinogenesis ,Internal medicine ,Gastrointestinal cancers (GIC) ,medicine ,In patient ,business - Abstract
First line therapies usually induce the longest progression free survival (PFS) in metastatic gastrointestinal cancers (GIC) as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sensitivity to conventional cancer therapy (CCT) after progression to IT and thereby, influence both tumor growth rate (TGR) and PFS. We have studied TGR and PFS before and after participation in phase I IT trials.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.